Head to Head Comparison: Invitae (NVTA) vs. Its Competitors

Invitae (NYSE: NVTA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Invitae to related companies based on the strength of its profitability, analyst recommendations, dividends, earnings, valuation, institutional ownership and risk.


How to Become a New Pot Stock Millionaire

This table compares Invitae and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invitae -180.85% -124.43% -68.92%
Invitae Competitors -118.64% -181.74% -42.76%

Valuation & Earnings

This table compares Invitae and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Invitae $68.22 million -$123.38 million -2.15
Invitae Competitors $1.13 billion $76.65 million 210.42

Invitae’s competitors have higher revenue and earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Invitae and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invitae 0 0 4 0 3.00
Invitae Competitors 109 458 535 18 2.41

Invitae currently has a consensus target price of $11.00, indicating a potential upside of 92.64%. As a group, “Medical laboratories” companies have a potential upside of 16.03%. Given Invitae’s stronger consensus rating and higher possible upside, research analysts plainly believe Invitae is more favorable than its competitors.

Risk & Volatility

Invitae has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Invitae’s competitors have a beta of 1.24, indicating that their average stock price is 24% more volatile than the S&P 500.

Institutional and Insider Ownership

71.4% of Invitae shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 8.7% of Invitae shares are owned by company insiders. Comparatively, 18.4% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Invitae competitors beat Invitae on 7 of the 12 factors compared.

Invitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply